Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1.
Anagha DeshpandeJavier MunozVrushali DabakAmr HanbaliRazelle KurzrockPublished in: Journal of immunotherapy and precision oncology (2024)
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that primarily causes the growth of tumors along nerves. Additionally, the germline mutations involved in NF1 predispose patients to develop further malignancies. The mainstay initial treatment for these malignancies is surgical removal at diagnosis, although targeted therapies are under evaluation in the relapsed setting. We report a case of malignant peripheral nerve sheath tumor (MPNST), gastrointestinal stromal tumor (GIST), and pheochromocytoma in a patient with NF1 who presented with an infected right shoulder lesion that was confirmed to be spindle cell sarcoma via biopsy. She was treated with antibiotics; however, she rapidly deteriorated and opted for hospice care. NF1 germline mutations increase the risk of patients developing various types of cancer. Recent studies have shown that there is a role for using MEK inhibitors such as selumetinib for treating patients with NF1.
Keyphrases
- signaling pathway
- lps induced
- end stage renal disease
- pi k akt
- newly diagnosed
- oxidative stress
- nuclear factor
- ejection fraction
- chronic kidney disease
- peripheral nerve
- peritoneal dialysis
- gene expression
- inflammatory response
- single cell
- toll like receptor
- cell therapy
- cell proliferation
- case report
- pain management
- dna methylation
- immune response
- hodgkin lymphoma
- combination therapy
- multiple myeloma
- squamous cell
- replacement therapy